Pharmaceutical Approval Update release_di6qn3lqgzhslfy2xgegh4msvq

by Michele B Kaufman

Published in P & T : a peer-reviewed journal for formulary management.

2016   Volume 41, Issue 10, p617-639


Obeticholic acid (Ocaliva) for primary biliary cholangitis; sofosbuvir 400 mg/velpatasvir 100 mg (Epclusa) for chronic hepatitis C virus infection; and daclizumab (Zinbryta) for relapsing multiple sclerosis.
In text/plain format

Archived Files and Locations

application/pdf  558.6 kB
file_hnn6rcjvrnfndaisxntuortiii (repository) (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Year   2016
Language   en ?
PubMed  27756999
PMC  PMC5046998
Journal Metadata
Not in DOAJ
Not in Keepers Registry
ISSN-L:  1052-1372
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 98aae904-bc6a-4548-8cbd-efe3c517b7c5